Mary C. Clouser

Mary C. Clouser

Auto-generated profile, based on publicly available information

Mary C. Clouser

Amgen, Thousand Oaks, CA, USA

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2016 in Military Medicine
Verified
Journal Article
Open access
JDJudy L. Dye
Judy L. Dye
SESusan L. Eskridge
Susan L. Eskridge
VTVictoria Tepe
Victoria Tepe
MCMary C. Clouser
Mary C. Clouser
MGMichael Galarneau
Michael Galarneau
Military Medicine is AMSUS’ monthly peer-reviewed journal, with articles including scientific papers, case reports, and editorials. Its objective is to promote awareness of federal medicine by providing a forum for responsible discussion of common ideas and problems relevant to federal healthcare.

19 July 2025 in Cancer Treatment and Research Communications
Verified
Journal Article
Open access
MCMary C. Clouser
Mary C. Clouser
MSMina Suh
Mina Suh
NMNaimisha Movva
Naimisha Movva
JHJanet S. Hildebrand
Janet S. Hildebrand
SPSusan T. Pastula
Susan T. Pastula
SYSoo-Ryum Yang
Soo-Ryum Yang
Methylthioadenosine phosphorylase (MTAP) deficiency is observed across multiple cancers and represents an emerging biomarker with therapeutic potential via synthetic lethality with PRMT5 inhibition. This systematic literature review summarizes the prevalence of MTAP deletions or loss of expression and prognostic impacts of MTAP deletions or loss in adult and pediatric patients with specific solid or hematologic cancers. Following PRISMA methodology, the literature on MTAP deletion or loss in multiple cancer types was reviewed. Prevalence, laboratory testing methods, patient characteristics, and clinical outcomes according to MTAP status were synthesized. Study quality was determined using standard tools. Of the 352 identified studies, 37 reported on MTAP. The majority were retrospective cohorts (N=32; 86%). The most common laboratory test type was NGS, specifically FoundationOne (N=7, 24%). MTAP deletion (loss) prevalence varied across tumor types and were generally lowest in gastric cancer (4%-14%) and highest in glioblastoma (26%-60%). MTAP deletion was correlated with higher prevalence of KRAS. Variation by age, gender, and race/ethnicity were inconsistently reported. Survival outcomes were reported most often for GBM and NSCLC with some studies suggesting worse overall survival among patients with MTAP deletions, although the evidence was heterogeneous. This is the first systematic review to summarize the literature on MTAP deletions or loss of expression across several solid and hematologic cancers. MTAP deletions and/or loss of expression occur in many cancer types, presenting a promising target for pan-cancer therapy.

1 January 2021 in Military Medicine
Verified
Journal Article
Open access
PDF file
AEAlec D Emerling
Alec D Emerling
WBWilliam Bianchi
William Bianchi
MKMichael Krzyzaniak
Michael Krzyzaniak
TDTravis Deaton
Travis Deaton
DVDarin Via
Darin Via
JAJonathan D Auten
Jonathan D Auten
Introduction: Rapid sequence intubation of patients experiencing traumatic hemorrhage represents a precarious phase of care, which can be marked by hemodynamic instability and pulseless arrest. Military combat trauma guidelines recommend reduced induction dose and early blood product resuscitation. Few studies have evaluated the role of induction dose and preintubation transfusion on hemodynamic outcomes. We compared rates of postintubation systolic blood pressure (SBP) of < 70 mm Hg, > 30% drop in SBP, pulseless arrest, and mortality at 24 hours and 30 days among patients who did and did not receive blood products before intubation and then examined if induction agent and dose influenced the same outcomes.Materials and Methods: A retrospective analysis was performed of battle-injured personnel presenting to surgical care facilities in Iraq and Afghanistan between 2004 and 2018. Those who received blood transfusions, underwent intubation, and had an Injury Severity Score of ≥15 were included. Intubation for primary head, facial, or neck injury, burns, operative room intubations, or those with cardiopulmonary resuscitation in progress were excluded. Multivariable logistic regression was performed with unadjusted and adjusted odds ratios for the five study outcomes among patients who did and did not receive preintubation blood products. The same analysis was performed for patients who received full or excessive versus partial induction agent dose.Results: A total of 153 patients had a mean age of 24.9 (SD 4.5), Injury Severity Score 29.7 (SD 11.2), heart rate 122.8 (SD 24), SBP 108.2 (SD 26.6). Eighty-one (53%) patients received preintubation blood products and had similar characteristics to those who did not receive transfusions. Adjusted multivariate analysis found odds ratios as follows: 30% SBP decrease 9.4 (95% CI 2.3-38.0), SBP < 70 13.0 (95% CI 3.3-51.6), pulseless arrest 18.5 (95% CI 1.2-279.3), 24-hour mortality 3.8 (95% CI 0.7-21.5), and 30-day mortality 1.3 (0.4-4.7). In analysis of induction agent choice and comparison of induction agent dose, no statistically significant benefit was seen.Conclusion: Within the context of this historical cohort, the early use of blood products conferred a statistically significant benefit in reducing postintubation hypotension and pulseless arrest among combat trauma victims exposed to traumatic hemorrhage. Induction agent choice and dose did not significantly influence the hemodynamic or mortality outcomes.

1 June 2023 in Clinical Epidemiology
Verified
Journal Article
Open access
PDF file
CLChase D Latour
Chase D Latour
LMLeah J McGrath
Leah J McGrath
MCMary Clouser
Mary Clouser
CNCarrie Nielson
Carrie Nielson
YYYing Yu
Ying Yu
MBM Alan Brookhart
M Alan Brookhart
Purpose: Regression-to-the-mean (RTM) is a statistical phenomenon that may occur in epidemiologic studies where inclusion in the study cohort is contingent upon experiencing a laboratory/clinical measurement beyond a defined threshold. When differential across treatment groups, RTM could bias the final study estimate. This poses substantial challenges in observational studies that index patients upon experiencing extreme laboratory or clinical values. Our objective was to investigate propensity score-based methods as a tool for mitigating this source of bias via simulation. Methods: We simulated a noninterventional comparative effectiveness study, comparing treatment with romiplostim to standard-of-care therapies for immune thrombocytopenia (ITP), a disease characterized by low platelet counts. Platelet counts were generated from normal distributions according to the underlying ITP severity, a strong confounder of treatment and outcome. Patients were assigned treatment probabilities based upon ITP severity, which created varied levels of differential and non-differential RTM. Treatments were compared via the difference in median platelet counts during 23 weeks of follow-up. We calculated four summary metrics of the platelet counts measured prior to cohort entry and built six propensity score models to adjust for those variables. We adjusted for these summary metrics using inverse probability of treatment weights. Results: Across all simulated scenarios, propensity score adjustment reduced bias and increased precision of the treatment effect estimator. Adjusting for combinations of the summary metrics was most effective at reducing bias. Adjusting for the mean of prior platelet counts or the difference between the cohort-qualifying platelet count and the largest prior count eliminated the most bias when assessed individually. Conclusion: These results suggest that differential RTM could be reasonably addressed by propensity score models with summaries of historical laboratory values. This approach can be easily applied to any comparative effectiveness or safety study, though investigators should carefully consider the best summary metric for their data.